<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965506</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI362A201</org_study_id>
    <nct_id>NCT04965506</nct_id>
  </id_info>
  <brief_title>A Study of IBI362 in Chinese Patients With Type 2 Diabetes</brief_title>
  <official_title>A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of IBI362 in Chinese&#xD;
      patients with Type 2 Diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in HbA1c from baseline to 20 weeks</measure>
    <time_frame>Baseline,20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving HbA1c Target of &lt;7.0%</measure>
    <time_frame>Baseline,20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>Baseline,25 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>IBI362 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive low dose IBI362 by subcutaneous (SC) injection once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI362 moderate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive medium dose IBI362 by subcutaneous (SC) injection once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulaglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive Dulaglutide 1.5mg by subcutaneous (SC) injection once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI362 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive high dose IBI362 by subcutaneous (SC) injection once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo by subcutaneous (SC) injection once a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI362</intervention_name>
    <description>IBI362 administered subcutaneously (SC) once a week.</description>
    <arm_group_label>IBI362 high dose</arm_group_label>
    <arm_group_label>IBI362 low dose</arm_group_label>
    <arm_group_label>IBI362 moderate dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo administered subcutaneously (SC) once a week.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Dulaglutide administered subcutaneously (SC) once a week.</description>
    <arm_group_label>Dulaglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have type 2 diabetes (T2DM) for ≥6 months according to the Criteria for Diagnosing&#xD;
             Type 2 Diabetes Mellitus (WHO 1999)&#xD;
&#xD;
          2. T2D patients with poorly controlled blood glucose treated with lifestyle intervention&#xD;
             or stable dose of metformin (≥ 1000mg/day or maximum tolerated dose) within 3 months&#xD;
             prior to screening.&#xD;
&#xD;
          3. Have HbA1c of 7.0% to 10.5%, inclusive(detected by local laboratory at screening).&#xD;
&#xD;
          4. Have a body mass index (BMI) between 20(Inclusive) and 40 kilograms per square meter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 diabetes, special types of diabetes, or gestational diabetes.&#xD;
&#xD;
          2. Have uncontrolled diabetes defined as more than 2 episodes of ketoacidosis or&#xD;
             hyperosmolar state requiring hospitalization in the 6 months prior to screening.&#xD;
&#xD;
          3. History of severe hypoglycemic episodes within 6 months prior to screening.&#xD;
&#xD;
          4. Have had any of the following within the last 6 months prior to screening: myocardial&#xD;
             infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary&#xD;
             intervention (diagnostic angiograms are permitted),transient ischemic attack (TIA),&#xD;
             cerebrovascular accident or decompensated congestive heart failure, or currently have&#xD;
             New York Health Association Class III or IV heart failure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>baiyi Yan</last_name>
    <phone>0512-69566088</phone>
    <email>baiyi.yan@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>China Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenying Yang</last_name>
      <phone>010-84205718</phone>
      <email>Ywying_1010@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

